Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RSBT 001

X
Drug Profile

RSBT 001

Alternative Names: RSBT-001

Latest Information Update: 12 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RS BioTherapeutics
  • Class Anti-inflammatories; Antifibrotics; Antihistamines; Cannabinoids
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Adult respiratory distress syndrome; Asthma; Bronchitis; Chronic obstructive pulmonary disease; Cystic fibrosis; Idiopathic pulmonary fibrosis; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 08 Jul 2024 RS BioTherapeutics and University of Colorado School of Medicine agree to co-develop RSBT 001 for Idiopathic Pulmonary Fibrosis and Chronic obstructive pulmonary disease
  • 17 May 2024 Pharmacodynamics data from a preclinical study in Idiopathic Pulmonary Fibrosis presented at the 120th International Conference of the American Thoracic Society (ATS-2024)
  • 18 Mar 2024 RS Biotherapeutics announces intention to initiate a clinical trial for Chronic obstructive pulmonary disease (COPD), SARS-COV-2 acute respiratory disease, Cystic fibrosis, Asthma, Bronchitis, and Acute respiratory distress syndrome in 2026
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top